Skip to main content
Print Save

Avapritinib Dosage

Medically reviewed by Drugs.com. Last updated on Mar 2, 2022.

Applies to the following strengths: 100 mg; 200 mg; 25 mg; 300 mg; 50 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Stomach Cancer

300 mg orally once a day until disease progression or unacceptable toxicity

Use: For the treatment of adults with unresectable or metastatic GIST harboring a
platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations

Renal Dose Adjustments

Mild (60 to less than 90 mL/min) to moderate (30 to less than 60 mL/min) renal impairment: No adjustment recommended.
Severe (15 to less than 30 mL/min) or end-stage (less than 15 mL/min) renal impairment: Data not available

Liver Dose Adjustments

Mild (total bilirubin less than or equal to upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin greater than 1 to 1.5 times ULN and any AST) or moderate (total bilirubin greater than 1.5 to 3 x ULN and any AST) hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Data not available

Dose Adjustments

RECOMMENDED DOSE REDUCTIONS:

  • First dose reduction: 200 mg orally once a day
  • Second dose reduction: 100 mg orally once a day
  • Permanently discontinue therapy in patients unable to tolerate 100 mg orally once a day.

RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS:
INTRACRANIAL HEMORRHAGE:
Grade 1 or 2:
  • First occurrence: Withhold this drug until resolution; resume at reduced dose.
  • Subsequent occurrence: Permanently discontinue this drug.
Grade 3 or 4:
  • Permanently discontinue this drug.
CENTRAL NERVOUS SYSTEM EFFECTS:
  • Grade 1: Continue at same dose or withhold until improvement to baseline or resolution; resume at same OR reduced dose.
  • Grade 2 or 3: Withhold this drug until improvement to baseline, Grade 1, or resolution; resume at same OR reduced dose.
Grade 4: Permanently discontinue therapy.
OTHER ADVERSE REACTIONS:
Grade 3 or 4: Withhold this drug until improvement to less than or equal to Grade 2; resume at same OR reduced dose.

Concomitant Use of Strong or Moderate CYP450 3A Inhibitors:
  • Avoid concomitant use of this drug with strong or moderate CYP450 3A inhibitors.
  • If concomitant use with a moderate CYP450 3A inhibitor cannot be avoided, reduce the starting dose of this drug from 300 mg once a day to 100 mg a day.

Precautions

CONTRAINDICATIONS:

  • None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
  • Do not take an additional dose if vomiting occurs after taking this drug but continue with the next scheduled dose.
  • If a dose is missed do not make up for a missed dose within 8 hours of the next
scheduled dose.

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions are permitted from 15C to 30C (59F to 86F).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer